Home > Boards > US Listed > Biotechs >

XTL Biopharmaceuticals Ltd. (XTLB)

Add XTLB Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/5/2021 5:23:54 PM - Followers: 19 - Board type: Free - Posts Today: 0

XTL Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of diabetic neuropathic pain and hepatitis C.

Our lead compound is Bicifadine. We are developing Bicifadine for the treatment of diabetic neuropathic pain, a chronic condition resulting from damage to peripheral nerves. In September 2007, we initiated a Phase 2b trial that is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain. Bicifadine is a serotonin and norepinephrine reuptake inhibitor, or SNRI. Compared to the currently approved SNRI's, Bicifadine has a unique ratio of serotonin versus norepinephrine reuptake inhibition, which is weighted toward norepinephrine reuptake inhibition, thereby providing a strong scientific rationale for testing Bicifadine for the treatment neuropathic pain indications. Prior to it being in-licensed, Bicifadine was extensively tested in more than 15 clinical trials involving over 3,000 patients, and has been shown to be safe and generally well tolerated. Bicifadine was evaluated in various acute pain indications, including two large, randomized clinical trials (n=750 and n=540) in patients suffering from acute post dental surgery pain, where Bicifadine demonstrated statistically significant efficacy. Bicifadine was also studied in chronic lower back pain studies, where it did not demonstrate statistically meaningful improvement in pain scores. Given the heterogeneity of the patient population, the diversity of sources of pain, and the significant psychological component, chronic lower back pain is considered a highly challenging pain model. XTL believes that a positive statistical and clinical benefit can be shown by assessing the drug's effect in a more homogenous and well-studied model such as diabetic neuropathic pain in which other SNRIs have been shown to be effective.

Our second program is the Diversity Oriented Synthesis, or DOS, program, which is focused on the development of novel pre-clinical hepatitis C small molecule inhibitors. Compounds developed to date inhibit HCV replication in a pre-clinical cell-based assay with potencies comparable to clinical stage drugs. In March 2008, we signed an agreement to out-license our DOS program to Presidio. Under the terms of the license agreement, Presidio becomes responsible for all further development and commercialization activities and costs relating to the DOS program. In accordance with the terms of the license agreement, we received a $4 million, non-refundable, upfront payment in cash from Presidio and will receive up to an additional $104 million upon reaching certain development and commercialization milestones. In addition, we will receive a royalty on direct product sales by Presidio, and a percentage of Presidio's income if the DOS program is sublicensed by Presidio to a third party.

Our Strategy

Under our current strategy, we plan to:

* complete our Phase 2b program for Bicifadine for the treatment of diabetic neuropathic pain;
* advance the development of Bicifadine towards approval in diabetic neuropathic pain and possibly in other related indications either alone or with a corporate partner; and
* seek to in-license or acquire additional candidates.

Shares Outstanding: 2.93M
Float: 1.43M
% Held by Insiders1: 293.97%
% Held by Institutions1: 47.30%
Market Cap (intraday)5: 10.09M
Enterprise Value (6-Jun-08)3: -4.26M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye 31-Dec-09) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 9.61
Price/Book (mrq): 1.02
Total Cash (mrq): 12.98M
Total Cash Per Share (mrq): 4.434
Total Debt (mrq): 0
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 2.589
Book Value Per Share (mrq): 2.93

Gallery View 4: (Full Sto, MACD, Aroon8)

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
XTLB News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 01/07/2021 09:10:07 AM
XTLB News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 12/31/2020 11:12:22 AM
XTLB News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 11/25/2020 10:43:54 AM
XTLB News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 11/12/2020 10:00:16 AM
#1879   * * $XTLB Video Chart 03-05-2021 * * ClayTrader 03/05/21 05:23:54 PM
#1878   Thanks for the link. Other boards seem to odds_are 03/05/21 09:53:52 AM
#1877   $XTLB is screaming for the top after a AlphaStockNews 03/05/21 07:28:31 AM
#1876   Good lord Awl416 03/05/21 07:01:52 AM
#1875   $1.70 nice wesley_ 06/15/20 03:08:19 PM
#1874   http://barchart.com/quotes/stocks/XTLBY PennyStock Alert 09/16/19 08:47:01 AM
#1873   * * $XTLB Video Chart 05-07-18 * * ClayTrader 05/07/18 05:08:01 PM
#1872   Boom!!! Joecanada13 05/07/18 12:34:31 PM
#1871   hmmm Tdash 06/30/17 09:53:23 AM
#1870   55k Awl416 02/16/17 08:23:19 AM
#1869   What was the volume AH yesterday? PAC 02/16/17 07:39:49 AM
#1868   There is some 3,50 Gifts europtiger 02/16/17 04:55:35 AM
#1867   Woow afterhour europtiger 02/15/17 04:49:25 PM
#1866   XTLB bullish 1.22 stocktrademan 08/11/16 10:09:32 AM
#1865   Whose driving this bus today, any catalyst here? GLTA!!! Yo-Yo 07/22/16 10:56:00 AM
#1864   Will def have this on my radar; ready fortunebuilder1959 10/02/14 10:29:48 PM
#1863   I must have missed the pump too Arizzle 10/02/14 06:16:56 PM
#1861   XTLB is a clear pump and dump based marcusjtrader 10/02/14 03:02:32 PM
#1860   Multi-day run? Arizzle 10/02/14 01:42:00 PM
#1859   http://finance.yahoo.com/news/xtl-biopharmaceuticals-further-strengthens-team-12 jcseattle 10/02/14 01:01:56 PM
#1858   (XTLB) Very good time to short it. jcseattle 10/02/14 12:56:58 PM
#1857   Boom...another pick skyrocket from BackPackOfStock AntiOne 10/02/14 12:27:51 PM
#1856   No idea Tradescott818 10/02/14 10:33:19 AM
#1855   What happen?. javier1973 10/02/14 10:25:34 AM
#1854   Wowwowowowowowowoowow Tradescott818 10/02/14 10:22:32 AM
#1853   Just picked a few shares....heard rumblings AntiOne 08/21/14 09:48:39 AM
#1852   8:02AM XTL Biopharma announced it has signed a surf1944 01/08/14 10:14:37 AM
#1851   XTLBY changed to XTLB and uplisted to the Renee 07/12/13 05:43:42 PM
#1850   XTLBY: 1-10 R/S concurrent with a ratio change. Renee 10/03/12 05:17:49 PM
#1849   Hello, Is there more information over XTLBY? Eugene_2009 07/04/12 03:20:42 PM
#1848   http://barchart.com/quotes/stocks/XTLBY Eugene_2009 07/04/12 06:32:55 AM
#1847   Hello to you as well. Sounds like the paulbk 06/06/12 01:04:52 PM
#1846   Hi paulbk - nice to know someone else odds_are 06/06/12 12:31:07 PM
#1845   You don't hear anything for years and suddenly this: paulbk 06/05/12 11:06:37 PM
#1844   Is there any news? Eugene_2009 09/24/10 06:43:01 AM
#1843   LOL!!!!!! My cousin's husband is fighting that rare cancer, Ecomike 09/23/10 10:23:59 PM
#1842   Other than this, I have no idea. Just deadjim 09/23/10 10:14:43 PM
#1841   Anyone have any clues as to what is Ecomike 09/23/10 09:25:45 PM
#1840   pops deadjim 07/31/10 10:46:53 PM
#1839   Let me know what you find. Volume spiked Ecomike 05/25/10 11:40:54 AM
#1838   This place looks dead. deadjim 04/27/10 04:45:57 AM
#1837   Well I am still holding mine. I suspect Ecomike 10/11/09 01:21:49 PM
#1836   Not really. There's not going to be anything paulbk 10/09/09 10:43:07 PM
#1835   Anybody here still following and holding this stock? Ecomike 10/08/09 02:42:23 AM
#1834   The 5 to 1 split on the TASE paulbk 06/23/09 02:10:28 AM
#1833   No sell off on the TASE on the paulbk 06/21/09 04:22:25 PM
#1832   Wow, older filings plainly state the ADR's were paulbk 06/17/09 01:04:28 PM
#1831   adding more here,showing strength. someone just posted new straycat 06/17/09 12:27:22 AM
#1830   I'm still here and holding. This little Fronko24 06/15/09 05:17:52 PM
#1829   still here,looks like we're just basing on a straycat 06/09/09 10:30:32 PM
Consent Preferences